Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 months...multiple sclerosis

AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...That's the sweet spot for a number of pharma companies...ERYtech Pharma SA, of Lyon, France, has had its prospectus accepted for a proposed initial public offering on the NYSE Euronext exchange in Paris

biotech to file for an initial public offering (IPO) this year, taking advantage of the emerging growth company provision in the Jumpstart Our Business Start-ups Act and aiming to raise as much as $86.3 million to support clinical work in multiple sclerosis, inflammatory bowel disease (IBD) and allergic/immune-mediate disorders...MEI Pharma Inc., of San Diego, priced a public offering of about 2 million shares of common stock at $7.50 apiece, a 9.5 percent discount to Thursday's closing price

Array BioPharma Inc., of Boulder, Colo., reported clinical data at the International Myeloma Workshop in Kyoto, Japan, showing that ARRY-520, a selective KSP inhibitor, demonstrated single-agent activity in heavily pretreated patients with relapsed or refractory multiple myeloma, with 19 months median overall survival and a 16 percent overall response rate...Cerulean Pharma Inc., of Cambridge, Mass., will present Phase II data for investigational nanopharmaceutical product CRLX101 at the American

Secondary objectives of the trial include clinical activity by serum TTR levels...For the Uceris 9-mg group, 17.4 percent of patients achieved clinical and endoscopic remission, compared to 4.5 percent of the placebo group (p = 0.0047...Virobay Inc., of Menlo Park, Calif., and Leo Pharma A/S, of Ballerup, Denmark, achieved a milestone in their collaboration on development of an oral therapy for psoriasis upon initiation of a Phase I trial of VBY-891 by Virobay

Cerulean Pharma Inc., of Cambridge, Mass., said CRLX101 achieved the predefined gating criterion for advancement into the second stage of a Phase II trial in advanced ovarian cancer...That allows Lorus to initiate a biomarker clinical investigation to further explore the effects of the drug at relevant doses determined in the trial...The complete clinical study report for the interim analysis would be supplied to the FDA during the review within 60 days of the resubmission

According Gregory Brown, founding managing director of HC Royalty, Nuron was seeking a combination of equity and nondilutive funding to support commercialization and expansion of Meningitec – an established vaccine to prevent invasive disease caused by Neisseria meningitidis serogroup C – and to advance HibTiter and NU100, its recombinant human interferon beta-1b in multiple sclerosis...As a small biotech with one foot in infectious disease and the other in neurology while having one hand in

EyeGate Pharma Inc., of Waltham, Mass., said it enrolled the last patient in a 200-subject pivotal Phase III study of EGP-437 (dexamethasone phosphate ophthalmic solution) in patients with anterior uveitis...The company is trying to reduce the cost of clinical trials by 50 percent or more, and is partnered with Advanced Monitored Caregiving, a telehealth provider, to that end...Study patients will have in-person visits with the clinical trial staff at the beginning and end of the trial, and all other

Accera Inc., of Broomfield, Colo., started a clinical efficacy trial examining the effects of AC-1204 in patients with mild-to-moderate Alzheimer's disease (AD...Apitope International NV, of Bristol, UK, completed recruitment in a Phase I trial of ATX-MS-1467, in multiple sclerosis, and triggered a milestone payment from partner Merck Serono SA, part of Darmstadt, Germany-based Merck KGaA...The FDA gave permission to Isotechnika Pharma Inc., of Edmonton, Alberta, to begin two Phase III trials of

Opexa Therapeutics Inc., of The Woodlands, Texas, said Health Canada approved its clinical trial application, enabling the company to expand its ongoing trial in secondary progressive multiple sclerosis (SPMS) to include several sites in Canada...Tiltan Pharma Ltd., of Jerusalem, said it enrolled the first U.S

The net proceeds will be used for working capital and general corporate purposes, including the continued conduct of the Abili-T clinical study, Opexa's recently initiated Phase IIb trial of personalized T-cell therapy Tcelna in patients with secondary progressive multiple sclerosis.

The firm posted net sales of alcohol dependence drug Vivitrol (naltrexone extended release) of $15.2 million and recorded royalty revenues from several products, including $3.3 million for Type II diabetes drug Bydureon (exenatide once weekly), $50.3 million from long-acting atypical antipsychotic drugs Risperdal Consta (risperidone) and Invega Sustenna (paliperidone palmitate) and $5 million for multiple sclerosis drug Ampyra (dalfampridine...Outside the U.S., Jakafi is marketed by partner

Acorda Therapeutics Inc., of Ardsley, N.Y., reported safety data from more than 62,400 people with multiple sclerosis (MS) taking Ampyra (dalfampridine) extended-release tablets during the first two years of availability in the U.S., with results showing a similar safety profile as observed in clinical trials...AlphaCore Pharma Inc., of Ann Arbor, Mich., said its Phase I trial met the primary endpoint by demonstrating the safety and tolerability of ACP-501 (recombinant human LCAT...The positive

If approved, the product, indicated for the treatment of autoimmune and inflammatory diseases, will enter clinical trials...Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, published Phase III results from the AFFIRM trial of enzalutamide (MDV3100) in metastatic castration-resistant prostate cancer patients previously treated with docetaxel-based chemotherapy in the New England Journal of Medicine...Disorders of circadian rhythm are implicated in a number of disorders including

Agenus Inc., of Lexington, Mass., said clinical data from a Phase I trial of a Prophage Series vaccine (HSPPC-96, vitespen) to treat patients with recurrent glioblastoma multiforme (GBM) were published online by Clinical Cancer Research...Clavis Pharma ASA, of Oslo, Norway, said its partner Clovis Oncology Inc., of Boulder, Colo., initiated a Phase I study of CP-4126 (CO-101) in combination with cisplatin in non-small-cell lung cancer (NSCLC

In a separate presentation, Novartis reported data from the Phase III FREEDOMS extension trial showing that Gilenya (fingolimod), an oral multiple sclerosis (MS) therapy, had significant improvements in clinical and MRI measures in patients who switched from placebo to Gilenya...The big pharma also presented results from a Phase II dose-finding study of BAF312 (siponimod), a selective modulator of the S1P receptor subtypes 1 and 5, in relapsing-remitting MS

Biogen Idec Inc., of Weston, Mass., presented additional data from its Phase III CONFIRM trial of oral BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis (MS) at the American Academy of Neurology meeting in New Orleans...Coronado Biosciences Inc., of Burlington, Mass., said development partner Dr. Falk Pharma GmbH, of Freiburg, Germany, disclosed the independent data monitoring committee's recommendation to continue Falk's Phase II trial in Europe evaluating Trichuris suis ova (TSO

Now we're making it easier for readers by separating pharma business and clinical news into these columns of brief news...Gilenya, a first-in-class sphingosine-1-phosphate (S1P) receptor modulator marketed by Novartis AG, of Basel, Switzerland, was approved by the FDA in 2010 to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability in patients with relapsing forms of multiple sclerosis

The company plans to start studies in multiple sclerosis patients within the next months...Zealand Pharma A/S, of Copenhagen, Denmark, said partner Sanofi SA, of Paris, disclosed top-line data from the GetGoal-P Phase III study, showing lixisenatide, a once-daily glucagon-like peptide 1 agonist, hit its primary efficacy endpoint of significantly reducing blood glucose levels compared to placebo (p < 0.0001), with HbA1c decreasing from a mean baseline value of 8.08 percent to a mean value of 7.06